EVAX

AI Memo

Evaxion A/S

As of 2026-09-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

EVX-01 three-year data at ESMO 2026 • 2026-12-01

Base target: $3 / p=50% prob

Biggest risk

EVX-01 data could disappoint on durability or stand-alone efficacy; EVX-05 is early preclinical; and ongoing business-development discussions may not convert into a deal. Cash burn and the eventual need for capital remain important downside risks.

Invalidation

Break below $2 or thesis failure.

What would change my mind?

Positive EVX-01 durability data at ESMO, continued platform validation, and a partnership could materially improve the financing and development outlook. The current deterministic prior is modestly positive, with expected returns of 0.67% over five days and 4.03% over 120 days, but uncertainty remains high.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-02

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 cash runway provides near-term funding visibility
Conversion of partnering discussions
Pipeline optionality from EVX-04 and EVX-05

BearKey bullets

Binary clinical readout risk around EVX-01 durability and stand-alone treatment results.
Business-development discussions have not yet produced an announced partnership.
EVX-05 remains early preclinical with no firm timeline for lead selection or IND-enabling work.

WatchKey bullets

EVX-01 three-year data at ESMO 2026

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $3 (p=50%)

Target spread vs base: +69% / -50%

Scenario probabilities

Bull Target: $5 (p=25%)Base Target: $3 (p=50%)Bear Target: $2 (p=25%)

Commentary

This is a low-coverage, event-driven monitoring setup. Evaxion's official investor-relations materials confirm the Q2 2026 update and the planned October ESMO EVX-01 data presentation [#PR-EARNINGS-2026-08-20]. Analyst revisions, options data, short interest, employee data, social coverage, and post-release market-reaction attribution remain unavailable. The deterministic score improved to a positive prior, but evidence quality remains only 0.34 and uncertainty is 0.763.

As of 2026-09-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 cash runway provides near-term funding visibility
Conversion of partnering discussions
Pipeline optionality from EVX-04 and EVX-05

Scenarios

Bull Target (Scenario probability)

$5 / p=25% prob

Base Target (Scenario probability)

$3 / p=50% prob

Bear Target (Scenario probability)

$2 / p=25% prob

Analysis 2026-09-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-12-01
EVX-01 three-year data at ESMO 2026
Evaxion plans to present three-year clinical efficacy and durability data for its personalized EVX-01 melanoma vaccine at the ESMO Congress in October 2026. This remains the clearest near-term value-setting event [#PR-EARNINGS-2026-08-20].
Prob 65.00% • Move 32.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Q2 cash runway provides near-term funding visibility
2026-12-01
The available Q2 2026 results context reports approximately $14 million of cash, a $3.7 million net loss, and runway into the second half of 2027. This reduces immediate financing pressure but does not eliminate future dilution risk [#PR-EARNINGS-2026-08-20].
Prob 65% • Move 8% • Priced-in 60%

Long-term Catalysts

Months to a year

Conversion of partnering discussions
2027-09-02
Management described ongoing discussions with potential partners around Evaxion programs and its AI-Immunology platform, but no partnership was announced in the available evidence [#EARNINGS-TRANSCRIPT-2026Q2].
Prob 25% • Move 25% • Priced-in 15%
Pipeline optionality from EVX-04 and EVX-05
2027-09-02
The company is expanding and refocusing its pipeline with EVX-04 AML preclinical work and the new EVX-05 glioblastoma program. EVX-05 remains early-stage with no firm development timeline in the packet [#PR-EARNINGS-2026-08-20].
Prob 40% • Move 20% • Priced-in 20%

Risks

Binary clinical readout risk around EVX-01 durability and stand-alone treatment results.
Business-development discussions have not yet produced an announced partnership.
EVX-05 remains early preclinical with no firm timeline for lead selection or IND-enabling work.
Low coverage, limited independent validation, and loose peers reduce confidence in valuation and sentiment signals.
Ongoing cash burn could require future financing or partnership capital despite runway into the second half of 2027.

Peers

Symbol	Summary
AYTU	Same-sector micro-cap size match; useful mainly for event-volatility context rather than as a direct clinical or platform peer.
ENLV	Same-sector micro-cap comparator with limited evidence of direct operating overlap; suitable only for broad biotech risk framing.
LGVN	Similar market-cap biotechnology candidate; peer fit is loose and should not anchor valuation.
OPTH	Same-sector size-based comparator; useful for micro-cap biotech trading context, not direct program comparison.
TVRD	Same-sector micro-cap comparator; relevant mainly to milestone and financing volatility framing.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-02

Loading AI feed…

Symbol

Summary

AYTU

Same-sector micro-cap size match; useful mainly for event-volatility context rather than as a direct clinical or platform peer.

ENLV

Same-sector micro-cap comparator with limited evidence of direct operating overlap; suitable only for broad biotech risk framing.

LGVN

Similar market-cap biotechnology candidate; peer fit is loose and should not anchor valuation.

OPTH

Same-sector size-based comparator; useful for micro-cap biotech trading context, not direct program comparison.

TVRD

Same-sector micro-cap comparator; relevant mainly to milestone and financing volatility framing.